|
|
Blood, 1 April 2004, Vol. 103, No. 7, pp. 2677-2682.
Prepublished online as a Blood First Edition Paper on November 20, 2003; DOI 10.1182/blood-2003-06-2070.
 Previous Article | Table of Contents | Next Article 
IMMUNOBIOLOGY
New CFSE-based assay to determine susceptibility to lysis by cytotoxic T cells of leukemic precursor cells within a heterogeneous target cell population
Inge Jedema,
Nicole M. van der Werff,
Renée M. Y. Barge,
Roel Willemze, and
J. H. Frederik Falkenburg
From the Department of Hematology, Laboratory of Experimental Hematology, Leiden University Medical Center, the Netherlands.
For the clinical evaluation of the efficacy of cellular immunotherapy it is necessary to analyze the effector functions of T cells against primary leukemic target cell populations which are usually considerably heterogeneous caused by differential maturation stages of the leukemic cells. An appropriate assay should not only allow the quantitative analysis of rapid cell death induction as measured by the conventional 51Cr release assay but also of the more slowly executing pathways of T-cell-induced apoptosis occurring within days instead of hours which cannot be measured using this method. Furthermore, it should dissect the differential susceptibility to T-cell-induced cell death of various target cell subpopulations and characterize the malignant precursor cells capable of producing malignant progeny. To fulfill these requirements we developed a new assay based on carboxyfluorescein diacetate succinimidyl ester (CFSE) labeling of the target cell population combined with antibody staining of specific cell populations and addition of fluorescent microbeads to quantitatively monitor target cell death occurring within a longer time frame up to at least 5 days. This new assay facilitates the analysis of differential recognition of distinct cell types within a heterogeneous target cell population and allows simultaneously evaluation of the proliferative status of surviving target cells in response to relevant cytokines. (Blood. 2004;103: 2677-2682)
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M.-H. Fortier, E. Caron, M.-P. Hardy, G. Voisin, S. Lemieux, C. Perreault, and P. Thibault
The MHC class I peptide repertoire is molded by the transcriptome
J. Exp. Med.,
March 17, 2008;
205(3):
595 - 610.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Griffioen, E. D. van der Meijden, E. H. Slager, M. W. Honders, C. E. Rutten, S. A. P. van Luxemburg-Heijs, P. A. von dem Borne, J. J. van Rood, R. Willemze, and J. H. F. Falkenburg
Identification of phosphatidylinositol 4-kinase type II {beta} as HLA class II-restricted target in graft versus leukemia reactivity
PNAS,
March 11, 2008;
105(10):
3837 - 3842.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Bastian, T. Braun, H. Bruns, M. Rollinghoff, and S. Stenger
Mycobacterial Lipopeptides Elicit CD4+ CTLs in Mycobacterium tuberculosis-Infected Humans
J. Immunol.,
March 1, 2008;
180(5):
3436 - 3446.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. F. de Vries, P. A. von dem Borne, S. A.P. van Luxemburg-Heijs, M. H.M. Heemskerk, R. Willemze, J.H. F. Falkenburg, and R. M.Y. Barge
Differential activation of the death receptor pathway in human target cells induced by cytotoxic T lymphocytes showing different kinetics of killing
Haematologica,
December 1, 2007;
92(12):
1671 - 1678.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Fiore, B. Castella, B. Nuschak, R. Bertieri, S. Mariani, B. Bruno, F. Pantaleoni, M. Foglietta, M. Boccadoro, and M. Massaia
Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid
Blood,
August 1, 2007;
110(3):
921 - 927.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Hurchla, J. R. Sedy, and K. M. Murphy
Unexpected Role of B and T Lymphocyte Attenuator in Sustaining Cell Survival during Chronic Allostimulation
J. Immunol.,
May 15, 2007;
178(10):
6073 - 6082.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. M. van Bergen, M. G. D. Kester, I. Jedema, M. H. M. Heemskerk, S. A. P. van Luxemburg-Heijs, F. M. Kloosterboer, W. A. E. Marijt, A. H. de Ru, M. R. Schaafsma, R. Willemze, et al.
Multiple myeloma-reactive T cells recognize an activation-induced minor histocompatibility antigen encoded by the ATP-dependent interferon-responsive (ADIR) gene
Blood,
May 1, 2007;
109(9):
4089 - 4096.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Jedema, P. Meij, E. Steeneveld, M. Hoogendoorn, B. A. Nijmeijer, M. van de Meent, S. A.P. van Luxemburg-Heijs, R. Willemze, and J.H. F. Falkenburg
Early Detection and Rapid Isolation of Leukemia-Reactive Donor T Cells for Adoptive Transfer Using the IFN-{gamma} Secretion Assay
Clin. Cancer Res.,
January 15, 2007;
13(2):
636 - 643.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Li, J. Melenhorst, N. Hensel, K. Rezvani, G. Sconocchia, Y. Kilical, J. Hou, B. Curfman, E. Major, and A. J. Barrett
T-cell responses to peptide fragments of the BK virus T antigen: implications for cross-reactivity of immune response to JC virus.
J. Gen. Virol.,
October 1, 2006;
87(Pt 10):
2951 - 2960.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. van Meerten, R. S. van Rijn, S. Hol, A. Hagenbeek, and S. B. Ebeling
Complement-Induced Cell Death by Rituximab Depends on CD20 Expression Level and Acts Complementary to Antibody-Dependent Cellular Cytotoxicity.
Clin. Cancer Res.,
July 1, 2006;
12(13):
4027 - 4035.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. H. Slager, M. W. Honders, E. D. van der Meijden, S. A. P. van Luxemburg-Heijs, F. M. Kloosterboer, M. G. D. Kester, I. Jedema, W. A. E. Marijt, M. R. Schaafsma, R. Willemze, et al.
Identification of the angiogenic endothelial-cell growth factor-1/thymidine phosphorylase as a potential target for immunotherapy of cancer
Blood,
June 15, 2006;
107(12):
4954 - 4960.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Hoogendoorn, J. Olde Wolbers, W. M. Smit, M. R. Schaafsma, I. Jedema, R. M.Y. Barge, R. Willemze, and J.H. F. Falkenburg
Primary Allogeneic T-Cell Responses against Mantle Cell Lymphoma Antigen-Presenting Cells for Adoptive Immunotherapy after Stem Cell Transplantation
Clin. Cancer Res.,
July 15, 2005;
11(14):
5310 - 5318.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Biagi, G. Dotti, E. Yvon, E. Lee, M. Pule, S. Vigouroux, S. Gottschalk, U. Popat, R. Rousseau, and M. Brenner
Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes
Blood,
March 15, 2005;
105(6):
2436 - 2442.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Zhang, G. Joe, E. Hexner, J. Zhu, and S. G. Emerson
Alloreactive Memory T Cells Are Responsible for the Persistence of Graft-versus-Host Disease
J. Immunol.,
March 1, 2005;
174(5):
3051 - 3058.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Jedema, E. Steeneveld, M. Hoogendoorn, R. Willemze, and J.H.F. Falkenburg
Depletion of In-Vivo Activated Regulatory T Cells Followed by Synchronized Specific In-Vitro Activation Allows the Rapid Isolation of Leukemia-Reactive T Cells for Immunotherapy.
Blood (ASH Annual Meeting Abstracts),
November 16, 2004;
104(11):
297 - 297.
[Abstract]
|
|
|
|
|
|
|
P. A. von dem Borne, S. A.P. van Luxemburg-Heijs, R. Willemze, and J.H. F. Falkenburg
Donor T-Cells Specific for Lineage-Restricted Maturation Antigens Not Recognizing Immature Progenitor Cells May Lead to Hematologic Remission but Molecular Persistence of Chronic Myeloid Leukemia (CML).
Blood (ASH Annual Meeting Abstracts),
November 16, 2004;
104(11):
1016 - 1016.
[Abstract]
|
|
|
|
|
|
|
M. Hoogendoorn, J. O. Wolbers, W. M. Smit, I. Jedema, M. R. Schaafsma, R. M.Y. Barge, R. Willemze, and J. H.F. Falkenburg
Primary Allogeneic T-Cell Responses Against In Vitro Modified Mantle Cell Lymphoma (MCL) Cells: Implications for Adoptive Immunotherapy after HLA-Matched Stem Cell Transplantation (SCT).
Blood (ASH Annual Meeting Abstracts),
November 16, 2004;
104(11):
2118 - 2118.
[Abstract]
|
|
|
|
|
